Partner Rare

THE ORPHAN DRUG DESIGNATION PLAYBOOK

Navigating the Path to Success

Dr. Scott N. Freeman, Ph.D.

Introduction

In the high-stakes world of pharmaceutical development, rare disease therapeutics present both extraordinary challenges as well as unprecedented opportunities. Since the landmark Orphan Drug Act of 1983, the FDA has granted over 7,000 orphan drug designations, with annual designations now exceeding 400. Yet behind these impressive numbers lies a sobering reality: only 14% of designated therapies ultimately achieve approval. This gap represents billions in unrealized potential—and more importantly, patients still waiting for treatments. [1]

During my tenure at the FDA reviewing over 100 ODD applications, I discovered a fundamental truth: success in this arena isn't left to chance. It is dependent upon solid science, strategic mastery of rare disease regulatory affairs, as well as commercial insight. This playbook combines Partner Rare's proven framework for transforming ODDs into approved therapies along with my expertise in regulatory strategy to inform winning patient-centered drug development.

Your paragraph text

The ODD Landscape: Growth and Global Expansion

The orphan drug designation landscape has experienced remarkable growth since 1983. Today, the FDA has granted over 7,000 designations—a 10% increase just since 2024.[1] This acceleration extends globally, with the European Medicines Agency (EMA) awarding more than 3,200 orphan medicinal product designations since 2000, and Japan's system approving 1,400 therapies since 1993.[2][3]

As previously noted, annual FDA designations now exceed 400, fueled by breakthroughs in precision medicine and attractive regulatory incentives. Development remains concentrated in oncology (42% of all orphan indications approved between 2010-2025), but pediatric rare diseases (18%) and neurologic disorders (14%) are gaining momentum thanks to gene therapy innovations.[4]

While opportunities abound, regulatory frameworks between different regulatory bodies diverge in critical ways:

Prevalence Thresholds

The FDA requires diseases affecting fewer than 200,000 US patients, while the EMA uses a threshold of fewer than 5 per 10,000 EU residents (approximately 246,000 total).

Benefit Requirements

The EMA demands proof of "significant benefit" over existing therapies for all submissions. The FDA only requires demonstration of "clinical superiority" if a sponsor is pursuing what is considered the "same drug" as an already approved drug for the same orphan indication—a critical distinction in strategic planning.

Exclusivity Periods

The FDA grants 7 years of market exclusivity, whereas the EMA offers 10 years (which can be reduced to 6 if a therapy becomes highly profitable).

These differences matter. To navigate them effectively, 33% of sponsors now pursue parallel FDA/EMA submissions, reducing approval delays by 18 months on average. [5] - [7]

Multi-Indication Strategies and Emerging Therapies

A quarter of orphan drugs hold two or more approved indications, with 18 drugs approved for five or more indications as of 2025. This trend is especially pronounced in oncology and autoimmune diseases, where targeted therapies often address multiple rare conditions. However, multi-indication development introduces distinct risks:

- **Exclusivity Challenges**
  63% of orphan drugs face competition from non-orphan indications within 5 years of approval. [9]
- **Pricing Pressures**
  Therapies with three or more indications face a 22% higher likelihood of payer reimbursement restrictions. [10] - [11]

Meanwhile, cell and gene therapies now represent 28% of new ODDs, up from just 9% in 2020, driven by innovations in CRISPR and AAV vectors. These advanced modalities face unique regulatory hurdles: manufacturing complexity (45% require additional CMC data versus 12% for small molecules), long-term safety concerns (particularly regarding insertional mutagenesis and immunogenicity), durability of response questions, and pediatric development challenges (only 10% include pediatric indications despite FDA incentives). Safety monitoring continues to be a primary focus for regulators, with many therapies requiring multi-year follow-up studies as a condition of approval. [12] - [13]

Crafting a Winning ODD Application

The most successful ODD applications balance divergent FDA and EMA requirements while anticipating evolving standards. Here's what works:

- **Prevalence Analysis:** The Foundation

  Inadequate epidemiologic models cause 37% of FDA application rejections.[14] Successful submissions combine

- **Reliable Literature Sources:**

  Peer-reviewed publications with the most current epidemiologic data

- **Current Prevalence:**

  Simple extrapolation from available prevalence data at the time of study to the time of submission

> It's important to note that simply stating "the disease is rare" without proper epidemiological calculations is insufficient. The FDA requires actual prevalence estimates with mathematical support, not just citations to literature that describes a condition as rare. Many applications fail precisely because they provide sources but don't connect them to a clear numerical estimate that falls below the 200,000-patient threshold.

Scientific Rationale: Making Your Case

The FDA requires scientifically valid evidence for the drug's potential effectiveness in the specific rare disease or condition. Acceptable forms of evidence include:

Studies in Animal Models

Data from studies in animals that accurately model the human disease, demonstrating drug activity relevant to the disease process

Human Case Studies

Well-documented case reports or small series showing improvement in patients treated with the drug

Clinical Trial Data

Results from Phase I/II trials showing effects on disease biomarkers or clinical outcomes

Purely theoretical mechanistic studies without evidence in disease models or patients are typically insufficient. The FDA evaluates whether there is a reasonable scientific basis to expect the drug may be effective, not proof of efficacy.

The EMA sets an even higher bar—72% of 2024 designations required human efficacy data, with 41% needing comparative effectiveness against standard care. [15]

Common Pitfalls to Avoid

Poor Disease Prevalence Estimates

Many applications fail due to inadequate prevalence calculations that either use outdated sources or fail to mathematically demonstrate that the condition affects fewer than 200,000 people in the U.S.

Similar but Not Identical Animal Models

Using animal models that don't precisely mirror the human disease condition may lead to rejection, as the FDA evaluates whether the model accurately represents the pathophysiology of the specific rare disease.

Inappropriate Orphan Subsets

Defining subsets of common diseases without medical or scientific justification for the subset is frequently rejected. Successful applications provide clear rationale for why the subset is medically distinct.

Inadequate Drug Sameness Assessment

Failing to analyze whether your product would be considered the "same drug" as an already-approved product by FDA standards, which involves specific chemical, biological, and functional comparisons.

Insufficient Clinical Superiority Justification

When addressing a "same drug/same disease" scenario, applications often fail by not adequately demonstrating why the new product would be clinically superior to the already-approved orphan drug.

Imprecise Disease Definitions

Applications that use overly broad or vague disease descriptions rather than recognized diagnostic classifications often face rejection.

Post-Submission Navigation

After submission, understanding the regulatory timeline and preparing for potential outcomes is crucial. The FDA typically completes review within 90 days, and applications generally face one of three outcomes: designation, deficiency letter, or denial.

Addressing FDA Deficiency Letters

If you receive a deficiency letter (which happens in approximately 40-50% of applications), focus on directly addressing the specific concerns raised rather than revising the entire application.

Common deficiencies include:

Prevalence Calculation Issues

Provide clearer mathematical derivation of your estimate and/or utilize other sources

Scientific Rationale Gaps

Submit additional data from animal models or clinical experience or clarify data already submitted

Disease Definition Ambiguities

Clarify diagnostic criteria and medical distinctness

The FDA allows sponsors one year to respond to deficiency letters. Take the time to gather appropriate data rather than rushing an inadequate response.

EMA Considerations

For EMA submissions, be aware that the timeline operates differently, with COMP (Committee for Orphan Medicinal Products) providing an initial opinion before final determination. The EMA places greater emphasis on comparative benefits against existing treatments, even non-orphan therapies.

Maintaining Your Designation

Post-designation, the FDA requires annual reports confirming continued interest in the designation and updating any significant development progress. These reports are straightforward but crucial; failure to file can result in designation withdrawal.

For products approaching approval, prepare early for potential post-marketing commitments, which are common with orphan drugs (especially for accelerated approvals).

The FDA increasingly focuses on:

- Long-term safety monitoring
- Confirmation of benefit in specific subpopulations
- Real-world effectiveness validation

By anticipating these requirements during development planning, you can design pivotal trials that satisfy both approval and post-approval needs, significantly reducing additional study costs.

Maximizing Commercial Potential

Beyond regulatory approval, commercial success for orphan drugs requires strategic planning across multiple dimensions:

Strategic Exclusivity Management

Orphan exclusivity (7 years US, 10 years EU) is valuable but must be actively protected. Consider:

- Timing supplemental indications strategically to extend overall exclusivity
- Using patents and other IP protections to complement regulatory exclusivity
- Planning for lifecycle management before first approval

Pricing & Reimbursement Strategy

Develop pricing strategies early considering:

- Value-based frameworks specific to rare diseases
- Early payer engagement to understand evidence requirements
- Patient assistance programs to address access barriers

Global Market Sequencing

Most successful orphan drugs follow strategic global rollouts:

US-first launches for 62% of orphan drugs

EU early access programs (ATUs in France, compassionate use in Italy) for revenue generation during review

Japan's price premium for first-to-market orphan drugs

By embedding commercial strategy into early development decisions, sponsors can significantly enhance ROI while ensuring patient access to much-needed therapies. The most successful orphan drug developers integrate development and commercial planning from the designation stage forward.

Conclusion

The orphan drug landscape offers extraordinary opportunities for those who navigate it strategically. While only 14% of designated therapies ultimately achieve approval, these successes represent both remarkable medical advances for patients and significant commercial value for developers.

Success in this arena requires mastery across multiple domains: regulatory science, clinical development, and commercial strategy. By understanding the nuances of prevalence documentation, crafting compelling scientific rationales, avoiding common pitfalls, and planning for post-designation challenges, sponsors can significantly improve their probability of success.

The path from promising compound to approved orphan therapy is demanding, but the rewards—measured in both lives improved and value created—are unmatched in the pharmaceutical industry. For patients awaiting treatments for conditions that have long been overlooked, every successful orphan drug represents hope transformed into reality.

As the regulatory landscape continues to evolve and scientific understanding of rare diseases deepens, those who approach orphan drug development with both scientific rigor and strategic foresight will be best positioned to deliver on the extraordinary promise of these specialized therapeutics.

About the Author

Dr. Scott Freeman, PhD.

Scott Freeman, PhD, is a regulatory affairs expert at Partner Rare, specializing in orphan drugs and rare disease therapeutics. His career is distinguished by a 95% first-submission success rate and nearly five years at the US FDA, where he served as a Health Science Administrator and FDA Commissioner's Fellow. He reviewed over 100 orphan drug applications and co-authored key FDA guidance. With a strong scientific foundation from Moffitt Cancer Centre and experience as CEO of FF Biotherapeutics, Scott brings a unique blend of regulatory expertise and scientific insight to accelerate the development and approval of therapies for rare diseases.

References

1. Search orphan drug designations and approvals. accessdata.fda.gov. (n.d.). https://www.accessdata.fda.gov/scripts/opdlisting/oopd/

2. European Commission. Community Register of Orphan Medicinal Products. Accessed March 2025.

3. Ministry of Health, Labour and Welfare (Japan). Orphan Drug Designation Status Reports. Accessed March 2025.

4. Fermaglich LJ, Miller KL. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act. Orphanet J Rare Dis. 2023 Jun 23;18(1):163. doi: 10.1186/s13023-023-02790-7. PMID: 37353796; PMCID: PMC10290406.

5. Kashoki, M., et al. (2019). A Comparison of EMA and FDA Decisions for New Drug Marketing Applications. Clinical Pharmacology & Therapeutics.

6. FDA & EMA. (2022). Parallel Scientific Advice (PSA) Program Review: 2017–2021.

7. CIRS R&D Briefing 81. (2025). New Drug Approvals in Six Major Authorities 2011–2025.

8. National Organization for Rare Disorders (NORD). (2020). Orphan Drugs in the United States: Rare Disease Innovation and Cost Trends Through 2019.

9. Health Affairs. Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Disease Approvals.

10. Institute for Clinical and Economic Review (ICER). The Next Generation of Rare Disease Drug Policy.

11. Journal of Managed Care & Specialty Pharmacy (JMCP). Meeting the Affordability Challenges Posed by Orphan Drugs.

12. FDA. Cell Gene Therapies Will 2025 Represent A Continuation Of FDA's 2024 Developments.

13. ASGCT. Optimizing Regulatory Frameworks for Gene Therapies in Rare Diseases.

14. AJMC. Unlocking the Benefits of FDA's Orphan Drug Designation.

15. EMA. Human Medicines Report 2024.

Partner Rare

let's talk rare | you'll hear the difference



www.partner-rare.com

info@partner-rare.com